Drugs / EBViNT Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03789617 | Dec 2018 → Sep 2022 | digestive system carcinoma, extranodal nasal NK/T cell lymphoma | Eutilex | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBViNT Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03789617 ↗ |
| Modality | Cell therapy | “EBV Specific Autologous CD8+ T Cell” NCT03789617 ↗ |
| Route | Intravenous | “Inject intravenously over 30 minutes” NCT03789617 ↗ |